Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase. Azilsartan medoxomil, in combination with the thiazide-like diuretic chlorthalidone, was more effective in lowering systolic BP than azilsartan plus HCTZ.
TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.
Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.
Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.
For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/ amlodipine, 20 mg/5 mg, respectively) will be orally administered once daily, before or after breakfast. For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/ amlodipine/amlodipine, 20 mg/5 mg/12.5 mg, respectively) will be orally administered once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg will be orally administered once daily, before or after breakfast.